Conventional structural imaging provides limited information on tumor characterization and prognosis. Advances in neurosurgical techniques, radiotherapy planning and novel drug treatments for brain tumors have generated increasing need for reproducible, non-invasive, quantitative, imaging biomarkers. This Review discusses the role of physiological MRI and PET molecular imaging in understanding metabolic processes associated with tumor growth, blood flow and ultrastructure.
- Adam D. Waldman
- Alan Jackson
- Jeremy H. Rees